Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00748657 · BASELINE

Baseline characteristics

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      36
    units
    Participants
groups
  1. description
    Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment
    id
    BG000
    title
    Bevacizumab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
      title
      20-29
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      30-39
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          8
      title
      40-49
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          12
      title
      50-59
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      60-69
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      70-79
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          0
      title
      80-89
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          36
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligibile and treatmed patients
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      36
    units
    Participants
groups
  1. description
    Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment
    id
    BG000
    title
    Bevacizumab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
      title
      20-29
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      30-39
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          8
      title
      40-49
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          12
      title
      50-59
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      60-69
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      70-79
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          0
      title
      80-89
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          36
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligibile and treatmed patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice